CD137, an attractive candidate for the immunotherapy of lung cancer

  • Cancer Sci. 2020 May;111(5):1461-1467. doi: 10.1111/cas.14354.
Lingyun Ye  1  2 ,  Keyi Jia  1  2 ,  Lei Wang  1 ,  Wei Li  1 ,  Bin Chen  1 ,  Yu Liu  1  2 ,  Hao Wang  1  2 ,  Sha Zhao  1 ,  Yayi He  1 ,  Caicun Zhou  1
Affiliations
  • 1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • 2. Medical school, Tongji University, Shanghai, China.
PMID: 32073704 DOI: 10.1111/cas.14354
Abstract

Immunotherapy has become a hotspot in Cancer therapy in recent years. Several immune checkpoints inhibitors have been used to treat Lung Cancer. CD137 is a kind of costimulatory molecule that mediates T cell activation, which regulates the activity of immune cells in a variety of physiological and pathological processes. Targeting CD137 or its ligand (CD137L) has been studied, aiming to enhance Anticancer immune responses. Accumulating studies show that anti-CD137 mAbs alone or combined with other drugs have bright antitumor prospects. In the following, we reviewed the biology of CD137, the antitumor effects of anti-CD137 Ab monotherapy and the combined therapy in Lung Cancer.

Keywords
CD137; CD137L; anti-CD137 monoclonal antibody; immune therapy; lung cancer.
Products